Bionano genomics announces the first publication using ogm to analyze impact of chromothripsis and tp53 abnormalities on chronic lymphocytic leukemia (cll) patients with high genomic complexity

San diego, aug. 25, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the publication of the first study to use optical genome mapping (ogm) to analyze the impact of chromothripsis (cth) and tp53 abnormalities on chronic lymphocytic leukemia (cll) patients with high genomic complexity. researchers aimed to determine whether poor prognostic outcomes observed in cases with cth might be related not only to the chromothriptic event itself but also to the presence of complex karyotypes or tp53 abnormalities.
BNGO Ratings Summary
BNGO Quant Ranking